| Natural killer cells in antitumour adoptive cell immunotherapy TJ Laskowski, A Biederstädt, K Rezvani Nature Reviews Cancer 22 (10), 557-575, 2022 | 495 | 2022 |
| KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape Y Li, R Basar, G Wang, E Liu, JS Moyes, L Li, LN Kerbauy, N Uprety, ... Nature medicine 28 (10), 2133-2144, 2022 | 108 | 2022 |
| SUMO pathway inhibition targets an aggressive pancreatic cancer subtype A Biederstädt, Z Hassan, C Schneeweis, M Schick, L Schneider, ... Gut 69 (8), 1472-1482, 2020 | 87 | 2020 |
| Engineering the next generation of CAR-NK immunotherapies A Biederstädt, K Rezvani International journal of hematology 114 (5), 554-571, 2021 | 83 | 2021 |
| RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction-a … S Lorenzen, A Biederstädt, U Ronellenfitsch, C Reißfelder, S Mönig, ... BMC cancer 20, 1-9, 2020 | 43 | 2020 |
| How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy A Biederstädt, K Rezvani Blood 141 (1), 22-38, 2023 | 28 | 2023 |
| Multiplexed engineering and precision gene editing in cellular immunotherapy A Biederstädt, GS Manzar, M Daher Frontiers in immunology 13, 1063303, 2022 | 11 | 2022 |
| CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis S Acharya, R Basar, M Daher, H Rafei, P Li, N Uprety, E Ensley, ... Cancer Discovery 14 (10), 1879-1900, 2024 | 8 | 2024 |
| Targeting T-cell lymphoma using CD70-directed cord blood-derived CAR-NK cells H Rafei, R Basar, S Acharya, P Zhang, P Liu, SM Moseley, P Li, M Daher, ... Blood 142, 4811, 2023 | 4 | 2023 |
| DAP10 Co-Stimulation Imparts Memory-like Features to CD5 Targeting Cord Blood Derived CAR-NK Cells R Basar, MD Daher, N Uprety, E Ensley, AK Nunez Cortes, S Acharya, ... Blood 142 (Supplement 1), 2089-2089, 2023 | 3 | 2023 |
| BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML B Kumar, A Singh, R Basar, N Uprety, Y Li, H Fan, AKN Cortes, M Kaplan, ... Science Translational Medicine 16 (764), eadp0004, 2024 | 2 | 2024 |
| Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G‐CSF versus G‐CSF only: A single‐center retrospective … V Dill, P Blüm, A Lindemann, A Biederstädt, M Högner, KS Götze, ... Transfusion 64 (5), 871-880, 2024 | 1 | 2024 |
| Epigenetic scarring leads to irreversible NK cell dysfunction in myeloid malignancies B Kumar, A Singh, R Basar, N Uprety, Y Li, H Fan, M Shanley, S Acharya, ... Blood 142 (Supplement 1), 2088-2088, 2023 | 1 | 2023 |
| 1502TiP Paclitaxel+ ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with … S Lorenzen, C Pauligk, TO Götze, C Michael, RJC Mahlberg, ... Annals of Oncology 31, S931, 2020 | 1 | 2020 |
| COMPARISON OF CE CHEMOTHERAPY PLUS G-CSF VS. G-CSF ALONE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER RETROSPECTIVE … M Hildebrandt, V Dill, P Bluem, A Lindemann, A Biederstaedt, M Hoegner, ... BONE MARROW TRANSPLANTATION 59, 657-658, 2024 | | 2024 |
| Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape Y Li, R Basar, G Wang, E Liu, JS Moyes, L Li, LN Kerbauy, N Uprety, ... Nature medicine 30 (3), 906, 2024 | | 2024 |
| KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (vol 28, pg 2133, 2022) Y Li, R Basar, G Wang, E Liu, JS Moyes, L Li, LN Kerbauy, N Uprety, ... NATURE MEDICINE, 2024 | | 2024 |
| NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis H Shaim, H Rafei, M Kaplan, R Basar, M Daher, M Shanley, P Banerjee, ... Blood 142, 1895, 2023 | | 2023 |
| Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant R Zeiser Blood 141 (1), 1-1, 2023 | | 2023 |
| RACE: Neoadjuvant chemoradiation vs. chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the esophagogastric junction S Lorenzen, A Biederstädt, C Pauligk, M Walker, U Ronellenfitsch, ... Forum 35, 337-339, 2020 | | 2020 |
